Analytical Data
-
基因名
ELOA3DP
- Application
-
种属
Human
-
表达系统
E. coli
-
标签
N- His & C- Myc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
A6NLF2
-
表达区间
270-429aa
-
分子量
25.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ELOA3DP, a protein derived from the ELOA gene family, has garnered significant attention in the field of molecular biology and biochemistry due to its unique structural characteristics and functional properties. Originally identified in studies focused on alternative splicing and post-translational modifications, ELOA3DP has been implicated in various physiological processes, including cell signaling, metabolism, and developmental regulation. Research has revealed that the restructured form of ELOA3DP exhibits enhanced stability and bioactivity, making it a promising candidate for therapeutic applications, particularly in regenerative medicine and disease models. The understanding of its molecular interactions and mechanisms of action has opened new avenues for targeting specific pathways involved in cellular dysfunctions. Furthermore, with the advancement of techniques such as CRISPR/Cas9 genome editing and protein engineering, researchers are now able to manipulate and study ELOA3DP with greater precision, paving the way for innovative strategies in drug design and therapeutic interventions. This growing body of research emphasizes the importance of ELOA3DP in the broader context of protein science and its potential impact on health and disease management, warranting further exploration and characterization of this innovative protein.
